- Global Pharma News & Resources

PDL BioPharma to Announce 2018 Fourth Quarter and Full Year Financial Results on March 14, 2019

INCLINE VILLAGE, Nev., March 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018, on Thursday, March 14, 2019, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m., Eastern time, to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at

Conference Call Details
To access the live conference call via phone, please dial (844) 535-4071 from the United States and Canada or (706) 679-2458 internationally. The conference ID is 5577359. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 5577359.

To access the live and subsequently archived webcast of the conference call, go to the Company's website and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma
PDL BioPharma seeks to provide a significant return for its stockholders through the acquisition, growth and potential monetization of a portfolio of actively managed pharmaceutical assets.  PDL is pursuing the acquisition of pharmaceutical products and companies that have the potential of generating significant shareholder value.  PDL is focused on commercial stage assets with multiple year revenue growth potential as well as late clinical stage pharmaceutical products.  For more information please visit


View original content to download multimedia:

SOURCE PDL BioPharma, Inc.

Editor Details

Last Updated: 07-Mar-2019